A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase

Oncogenes and signal transduction

Cantley, L. C., Auger, K. R., Carpenter, C. F., Duckworth, B. C., Graziani, A., Kapeller, R., & Soltoff, S. P. (1991) · Cell · doi:10.1016/0092-8674(91)90639-g · Cited by 2,697

Growth Factors and Cancer

Aaronson, S. A. (1991) · Science · doi:10.1126/science.1659742 · Cited by 2,017

Growth factor signaling by receptor tyrosine kinases

Schlessinger, J., & Ullrich, A. (1992) · Neuron · doi:10.1016/0896-6273(92)90177-f · Cited by 1,418

RECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENS

Carpenter, G. F. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004313 · Cited by 1,282

Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors

Morrison, J. F. (1969) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(69)90420-3 · Cited by 815

Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast

Sandgren, E. P., Luetteke, N., Palmiter, R. D., Brinster, R. L., & Lee, D. C. (1990) · Cell · doi:10.1016/0092-8674(90)90075-p · Cited by 752

TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas

Jhappan, C., Stahle, C., Harkins, R. N., Fausto, N., Smith, G. H., & Merlino, G. T. (1990) · Cell · doi:10.1016/0092-8674(90)90076-q · Cited by 709

DIOGENES SYNDROME

Clark, A. N. G., Mankikar, G. D., & Gray, I. (1975) · The Lancet · doi:10.1016/s0140-6736(75)91280-5 · Cited by 697

EPIDERMAL-GROWTH-FACTOR RECEPTORS IN HUMAN BLADDER CANCER: COMPARISON OF INVASIVE AND SUPERFICIAL TUMOURS

Neal, D. E., Bennett, M., Hall, R. R., Marsh, C., Abel, P., Sainsbury, J. R. C., & Harris, A. L. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91386-8 · Cited by 604

Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies

Masui, H., Kawamoto, T., Sato, J., Wolf, B., SATO, G. H., & Mendelsohn, J. M. (1984) · The Journal of Urology · doi:10.1016/s0022-5347(17)50005-1 · Cited by 446

Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

Kraker, A. J., Hartl, B. G., Amar, A. M., Barvian, M. R., Showalter, H. D., & Moore, C. W. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00405-6 · Cited by 140

Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies

Tan, F., Shen, X., Wang, D., Xie, G., Zhang, X., Ding, L., Hu, Y., He, W., Wang, Y., & Wang, Y. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.10.023 · Cited by 136

Progress of the synthesis of condensed pyrazole derivatives (from 2010 to mid-2013)

Li, M., & Zhao, B. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.102 · Cited by 134

Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction

Yang, H., Kim, S.-K., Kim, M., Reche, P. A., Morehead, T. J., Damon, I. K., Welsh, R. M., & Reinherz, E. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523220 · Cited by 134

Firefly Luciferase in Chemical Biology: A Compendium of Inhibitors, Mechanistic Evaluation of Chemotypes, and Suggested Use As a Reporter

Thorne, N., Shen, M., Lea, W., Simeonov, A. M., Lovell, S., Auld, D. S., & Inglese, J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.015 · Cited by 133

Targeting signal transduction for disease therapy

Levitzki, A. (1996) · Medical Oncology · doi:10.1007/bf02990952 · Cited by 133

p53 induction of heparin‐binding EGF‐like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades

Li, F., Li, G., Liu, G., Lee, S. W., & Aaronson, S. A. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1931 · Cited by 131

Pharmaceutical research in molecular oncology

Gibbs, J. (1994) · Cell · doi:10.1016/0092-8674(94)90189-9 · Cited by 132

Kinase Inhibitors of Marine Origin

Bharate, S. B., Sawant, S. D., Singh, P. P., & Vishwakarma, R. A. (2013) · Chemical Reviews · doi:10.1021/cr300410v · Cited by 132

Inhibition of the Epidermal Growth Factor Receptor Family of Tyrosine Kinases as an Approach to Cancer Chemotherapy

Fry, D. W. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00050-3 · Cited by 129

Phosphorylation Site-Specific Inhibition of Platelet-Derived Growth Factor β-Receptor Autophosphorylation by the Receptor Blocking Tyrphostin AG1296

Kovalenko, M. V., Rönnstrand, L., Heldin, C., Loubtchenkov, M., Gazit, A., Levitzki, A., & Böhmer, F. (1997) · Biochemistry · doi:10.1021/bi962553l · Cited by 129

Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment

Woodworth, C. D., Michael, E., Marker, D. F., Allen, S. E., Smith, L., & Nees, M. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0238 · Cited by 127

Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.

Li, B., Chang, C.-M., Yuan, M., McKenna, W. G., & Shu, H. G. (2003) · PubMed · Cited by 125

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors

Juchum, M., Günther, M., & Laufer, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.002 · Cited by 126

Epigenetic variation in the Egfr gene generates quantitative variation in a complex trait in ants

Alvarado, S. G., Rajakumar, R., Abouheif, E., & Szyf, M. (2015) · Nature Communications · doi:10.1038/ncomms7513 · Cited by 130

The Membrane Fusion Step of Vaccinia Virus Entry Is Cooperatively Mediated by Multiple Viral Proteins and Host Cell Components

Laliberte, J. P., Weisberg, A. S., & Moss, B. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002446 · Cited by 122

Activation of the Epidermal Growth Factor (EGF) Receptor Induces Formation of EGF Receptor- and Grb2-Containing Clathrin-Coated Pits

Johannessen, L. E., Pedersen, N. M., Pedersen, K. W., Madshus, I. H., & Stang, E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.26.2.389-401.2006 · Cited by 123

Microwave-Promoted Syntheses of Quinazolines and Dihydroquinazolines from 2-Aminoarylalkanone O-Phenyl Oximes

Portela‐Cubillo, F., Scott, J. S., & Walton, J. C. (2009) · The Journal of Organic Chemistry · doi:10.1021/jo900629g · Cited by 121

Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.

Lichtner, R. B., Menrad, A., Sommer, A., Klar, U., & Schneider, M. R. (2001) · PubMed · Cited by 121

Oncogenic Ras Blocks Anoikis by Activation of a Novel Effector Pathway Independent of Phosphatidylinositol 3-Kinase

McFall, A., ülkuü, A., Lambert, Q. T., Kusa, A., Rogers-Graham, K., & Der, C. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.16.5488-5499.2001 · Cited by 120

From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents

Morin, M. J. (2000) · Oncogene · doi:10.1038/sj.onc.1204102 · Cited by 120

Identification of Epidermal Growth Factor Receptor and c-erbB2 Pathway Inhibitors by Correlation With Gene Expression Patterns

Wosikowski, K., Schuurhuis, D. H., Johnson, K., Bates, S. E., Paull, K. D., Myers, T. G., & Weinstein, J. N. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.20.1505 · Cited by 119

Novel approaches with targeted therapies in bladder cancer

Joaquim Bellmunt, B., Hussain, M., & Dinney, C. P. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(03)00067-2 · Cited by 119

In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery.

Hernández-Alcoceba, R., Fernández, F., & Lacal, J. C. (1999) · PubMed · Cited by 118

A Raf-independent Epidermal Growth Factor Receptor Autocrine Loop Is Necessary for Ras Transformation of Rat Intestinal Epithelial Cells

Gangarosa, L. M., Sizemore, N., Graves‐Deal, R., Oldham, S., Der, C. J., & Coffey, R. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.18926 · Cited by 118

Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor

Rao, G., Murray, S., & Ethier, S. P. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01358-4 · Cited by 117

Bifunctional Ionic Liquids Derived from Biorenewable Sources as Sustainable Catalysts for Fixation of Carbon Dioxide

Saptal, V. B., & Bhanage, B. M. (2016) · ChemSusChem · doi:10.1002/cssc.201601228 · Cited by 117

Metal- and Oxidant-Free Synthesis of Quinazolinones from β -Ketoesters with o -Aminobenzamides via Phosphorous Acid-Catalyzed Cyclocondensation and Selective C–C Bond Cleavage

Li, Z., Dong, J., Chen, X., Li, Q., Zhou, Y., & Yin, S. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b00937 · Cited by 116

Cyclic stretch activates ERK1/2 via G proteins and EGFR in alveolar epithelial cells

Correa-Meyer, E., Pesce, L. M., Guerrero, C., & Sznajder, J. I. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00203.2001 · Cited by 116

Mechanism of von Hippel-Lindau Protein-Mediated Suppression of Nuclear Factor kappa B Activity

An, J., & Rettig, M. B. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7546-7556.2005 · Cited by 118

A role for phospholipase C-gamma-mediated signaling in tumor cell invasion.

Kassis, J. N., Moellinger, J., Lo, H., Greenberg, N. M., Kim, H., & Wells, A. H. (1999) · PubMed · Cited by 116

Effect of Tyrosine Kinase Inhibitors on Clathrin-coated Pit Recruitment and Internalization of Epidermal Growth Factor Receptor

Sorkina, T., Huang, F., Beguinot, L., & Sorkin, A. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201595200 · Cited by 115

Leukemic transformation of normal murine erythroid progenitors: v- and c-ErbB act through signaling pathways activated by the EpoR and c-Kit in stress erythropoiesis

Lindern, M. V., Deiner, E. M., Dolznig, H., Amelsvoort, M. P.-V., Hayman, M. J., Müllner, E. W., & Beug, H. (2001) · Oncogene · doi:10.1038/sj.onc.1204494 · Cited by 115

Mutation of Threonine 766 in the Epidermal Growth Factor Receptor Reveals a Hotspot for Resistance Formation against Selective Tyrosine Kinase Inhibitors

Blencke, S., Ullrich, A., & Daub, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211158200 · Cited by 117

Epidermal Growth Factor Receptor Is Not Required for Human Cytomegalovirus Entry or Signaling

Isaacson, M. K., Feire, A. L., & Compton, T. (2007) · Journal of Virology · doi:10.1128/jvi.00169-07 · Cited by 112

Modulation of tumor cell gene expression and phenotype by the organspecific metastatic environment

Radinsky, R. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690601 · Cited by 108

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)

Discafani, C. M., Carroll, M. L., Floyd, M. B., Hollander, I. J., Husain, Z., Johnson, B. D., Kitchen, D., May, M. K., Malo, M. S., Minnick, A. A., et al. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00356-6 · Cited by 112

Molecular mechanisms of radiation-induced accelerated repopulation

Schmidt‐Ullrich, R., Contessa, J. N., Dent, P., Mikkelsen, R. B., Valerie, K. C., Reardon, D. B., Bowers, G. D., & Lin, P. (1999) · Radiation Oncology Investigations · doi:10.1002/(sici)1520-6823(1999)7:6 · Cited by 110

Synthesis of condensed quinolines and quinazolines as DNA ligands

Malecki, N., Carato, P., Rigo, B., Goossens, J., Houssin, R., Bailly, C., & Hénichart, J. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.10.014 · Cited by 108

Heparin-binding ligands mediate autocrine epidermal growth factor receptor activation In skin organ culture.

Stoll, S., Garner, W. L., & Elder, J. T. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119641 · Cited by 108

E-Cadherin Binding Modulates EGF Receptor Activation

Fedor‐Chaiken, M., Hein, P. W., Stewart, J. C., Brackenbury, R. W., & Kinch, M. S. (2003) · Cell Communication & Adhesion · doi:10.1080/cac.10.2.105.118 · Cited by 107

Relaxin signalling links tyrosine phosphorylation to phosphodiesterase and adenylyl cyclase activity

Bartsch, O. (2001) · Molecular Human Reproduction · doi:10.1093/molehr/7.9.799 · Cited by 106

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

Allen, L. F., Lenehan, P. F., Eiseman, I. A., Elliott, W. L., & Fry, D. J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70122-x · Cited by 121

Tyrosine kinases as targets for cancer therapy

Levitzki, A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80598-6 · Cited by 107

Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives

Yang, E. B., Guo, Y. J., Zhang, K., Chen, Y., & Mack, P. (2001) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(01)00276-x · Cited by 103

Autocrine-mediated Activation of STAT3 Correlates with Cell Proliferation in Breast Carcinoma Lines

Li, L., & Shaw, P. E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109962200 · Cited by 102

Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross‐talking with RANK signaling

Yi, T., Lee, H., Cha, J., Ko, S., Kim, H., Shin, H., Woo, K. M., Ryoo, H., Kim, G., & Baek, J. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21511 · Cited by 103

Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy

Scambia, G., Benedetti-Panici, P., Ferrandina, G., Distefano, M., Salerno, G., Romanini, M., Fagotti, A., & Mancuso, S. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.339 · Cited by 101

The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors

Rusch, V. W., Mendelsohn, J. M., & Dmitrovsky, E. (1996) · Cytokine & Growth Factor Reviews · doi:10.1016/1359-6101(96)00016-0 · Cited by 101

I 2 -Catalyzed Aerobic Oxidative C(sp 3 )–H Amination/C–N Cleavage of Tertiary Amine: Synthesis of Quinazolines and Quinazolinones

Yan, Y., Xu, Y., Niu, B., Xie, H., & Liu, Y. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b00474 · Cited by 99

Pharmaceutical intervention in the JAK/STAT signaling pathway

Seidel, H. M., Lamb, P., & Rosen, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203550 · Cited by 97

Structure-based design of cyclin-dependent kinase inhibitors

Davies, T. G., Pratt, D. J., Endicott, J., Johnson, L. N., & Noble, M. E. M. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00182-1 · Cited by 97

In Vitro Pharmacological Characterization of PD 166285, a New Nanomolar Potent and Broadly Active Protein Tyrosine Kinase Inhibitor

Panek, R. L., Lu, G. H., Klutchko, S. R., Batley, B. L., Dahring, T. K., Hamby, J. M., Hallak, H., Doherty, A. M., & Keiser, J. A. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37140-x · Cited by 96

Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates

Marvania, B., Lee, P., Chaniyara, R., Dong, H., Suman, S., Kakadiya, R., Chou, T., Lee, T., Shah, A. K., & Su, T. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.01.055 · Cited by 96

Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells.

Jones, G., Machado, J., & Merlo, A. U. (2001) · PubMed · Cited by 96

Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.

Kelloff, G. J., Fay, J. R., Steele, V. E., Lubet, R., Boone, C. W., Crowell, J. A., & Sigman, C. C. (1996) · PubMed · Cited by 96

Molecular Basis for p38 Protein Kinase Inhibitor Specificity

Lisnock, J., Tebben, A., Frantz, B., O’Neill, E. A., Croft, G. F., O’Keefe, S. J., Li, B., Hacker, C., de Laszlo, S. E., Smith, A. J., et al. (1998) · Biochemistry · doi:10.1021/bi981591x · Cited by 95

EGF transactivation of Trk receptors regulates the migration of newborn cortical neurons

Puehringer, D., Orel, N., Lüningschrör, P., Subramanian, N., Herrmann, T., Chao, M. V., & Sendtner, M. (2013) · Nature Neuroscience · doi:10.1038/nn.3333 · Cited by 96

Hepatitis B Virus X Protein Differentially Activates RAS-RAF-MAPK and JNK Pathways in X-transforming Versus Non-transforming AML12 Hepatocytes

Tarn, C., Lee, S., Hu, Y., Ashendel, C. L., & ANDRISANI, O. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104105200 · Cited by 92

Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer

Khalil, M. Y., Grandis, J. R., & Shin, D. M. (2003) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.3.3.367 · Cited by 92

Asbestos-induced phosphorylation of epidermal growth factor receptor is linked to c-fosand apoptosis

Zanella, C. L., Timblin, C. R., Cummins, A. B., Jung, M., Goldberg, J. L., Raabe, R., Tritton, T. R., & Mossman, B. T. (1999) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1999.277.4.l684 · Cited by 92

Stimulation of β1-Integrin Function by Epidermal Growth Factor and Heregulin-β Has Distinct Requirements for erbB2 but a Similar Dependence on Phosphoinositide 3-OH Kinase

Adelsman, M. A., McCarthy, J. B., & Shimizu, Y. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.9.2861 · Cited by 91

NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways

Daly, J. M., Olayioye, M. A., Wong, A. M.-L., Neve, R. M., Lane, H. A., Maurer, F. G., & Hynes, N. E. (1999) · Oncogene · doi:10.1038/sj.onc.1202700 · Cited by 91

Cyclic stretch activates p38 SAPK2-, ErbB2-, and AT1-dependent signaling in bladder smooth muscle cells

Nguyen, H. T., Adam, R. M., Bride, S. H., Park, J. M., Peters, C. A., & Freeman, M. R. (2000) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2000.279.4.c1155 · Cited by 90

Oxidants and Antioxidants in Cutaneous Biology

Thiele, J. J., & Elsner, P. U. (2000) · Current problems in dermatology · doi:10.1159/isbn.978-3-318-00629-2 · Cited by 90

Reversible addition–fragmentation chain transfer synthesis of amidine‐based, CO2‐responsive homo and AB diblock (Co)polymers comprised of histamine and their gas‐triggered self‐assembly in water

Quek, J. Y., Roth, P. J., Evans, R. A., Davis, T. P., & Lowe, A. B. (2012) · Journal of Polymer Science Part A Polymer Chemistry · doi:10.1002/pola.26397 · Cited by 90

Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase

Bonasera, T. A., Ortu, G., Rozen, Y., Krais, R., Freedman, N. M. T., Chisin, R., Gazit, A., Levitzki, A., & Mishani, E. (2001) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(01)00200-1 · Cited by 87

Protein tyrosine kinases: Structure, substrate specificity, and drug discovery

Al‐Obeidi, F., Wu, J. J., & Lam, K. S. (1998) · Biopolymers · doi:10.1002/(sici)1097-0282(1998)47:3 · Cited by 88

Uncoupling between Epidermal Growth Factor Receptor and Downstream Signals Defines Resistance to the Antiproliferative Effect of Gefitinib in Bladder Cancer Cells

Kassouf, W., Dinney, C. P., Brown, G. A., McConkey, D. J., Diehl, J. A., Bar‐Eli, M., & Adam, L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1536 · Cited by 86

Comparison of Paclitaxel-, 5-Fluoro-2′-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis

Kottke, T. J., Blajeski, A. L., Martins, L. M., Mesner, P. W., Davidson, N. E., Earnshaw, W. C., Armstrong, D. K., & Kaufmann, S. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.22.15927 · Cited by 88

In Vitro Biological Characterization and Antiangiogenic Effects of PD 166866, a Selective Inhibitor of the FGF-1 Receptor Tyrosine Kinase

Panek, R. L., Lu, G. H., Dahring, T. K., Batley, B. L., Connolly, C. J. C., Hamby, J. M., & Brown, K. J. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37619-0 · Cited by 86

Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer

Nemunaitis, J. J., Eiseman, I. A., Cunningham, C. C., Senzer, N. N., Williams, A., Lenehan, P. F., Olson, S. C., Bycott, P. W., Schlicht, M., Zentgraff, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1950 · Cited by 84

TGF‐β cooperates with TGF‐α to induce the self–renewal of normal erythrocytic progenitors: evidence for an autocrine mechanism

Gandrillon, O., Schmidt, U., Beug, H., & Samarut, J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.10.2764 · Cited by 95

Solid phase synthesis of chiral 3-substituted quinazoline-2,4-diones

Gouilleux, L., Fehrentz, J., Winternitz, F., & Martínez, J. (1996) · Tetrahedron Letters · doi:10.1016/0040-4039(96)01541-9 · Cited by 85

EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells

Čamaj, P., Seeliger, H., Ischenko, I., Krebs, S., Blum, H., Toni, E. N. D., Faktorová, D., Jauch, K., & Bruns, C. J. (2009) · Biological Chemistry · doi:10.1515/bc.2009.140 · Cited by 83

UVB-induced Epidermal Growth Factor Receptor Phosphorylation is Critical for Downstream Signaling and Keratinocyte Survival ¶

Péus, D., Vasa, R. A., Meves, A., Beyerle, A., & Pittelkow, M. R. (2000) · Photochemistry and Photobiology · doi:10.1562/0031-8655(2000)0720135uiegfr2.0.co2 · Cited by 84

Maximal β3-Adrenergic Regulation of Lipolysis Involves Src and Epidermal Growth Factor Receptor-dependent ERK1/2 Activation

Robidoux, J., Kumar, N., Daniel, K. W., Moukdar, F., Cyr, M., Medvedev, A. V., & Collins, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605572200 · Cited by 82

Bifunctional Ionic Liquids for the Multitask Fixation of Carbon Dioxide into Valuable Chemicals

Saptal, V. B., & Bhanage, B. M. (2015) · ChemCatChem · doi:10.1002/cctc.201501044 · Cited by 81

Synthesis and in vitro antitumor evaluation of primary amine substituted quinazoline linked benzimidazole

Paul, K., Sharma, A., & Luxami, V. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.005 · Cited by 79

Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)

Sewell, J. M., Macleod, K. G., Ritchie, A., Smyth, J. F., & Langdon, S. P. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600058 · Cited by 79

Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells☆☆☆

Karnes, W. E., Weller, S. G., Adjei, P. N., Kottke, T. J., Glenn, K. S., Gores, G. J., & Kaufmann, S. H. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70312-9 · Cited by 79

Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily

Gandin, V., Ferrarese, A., Via, M. D., Marzano, C., Chilin, A., & Marzaro, G. (2015) · Scientific Reports · doi:10.1038/srep16750 · Cited by 80

Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration–Approved Drugs

Coussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, G. S., Simeonov, A. M., & Hall, M. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013755 · Cited by 80

Synthesis, antitumor activity and molecular docking study of some novel 3-benzyl-4(3H)quinazolinone analogues

Al-Suwaidan, I. A., Abdel‐Aziz, A. A. ‐., Shawer, T. Z., Ayyad, R. R. A., Alanazi, A. M., Morsy, A. M. E., Mohamed, M. A., Abdel-Aziz, N. I., El‐Sayed, M. A. ‐., & El‐Azab, A. S. (2015) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2015.1004059 · Cited by 78

In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.

Uckun, F. M., Narla, R. K., Zeren, T., Yanishevski, Y., Myers, D. E., Waurzyniak, B. J., Ek, R. O., Schneider, E., Messinger, Y. H., Chelstrom, L. M., et al. (1998) · PubMed · Cited by 78

Vasopressin-mediated mitogenic signaling in intestinal epithelial cells

Chiu, T. T., Wu, S. S., Santiskulvong, C., Tangkijvanich, P., Yee, H. F., & Rozengurt, E. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00240.2001 · Cited by 78

Mechanism of action of erbB tyrosine kinase inhibitors

Fry, D. W. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00095-2 · Cited by 78

Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications

Shaban, N., Kamashev, D., Emelianova, A., & Buzdin, A. A. (2023) · Cells · doi:10.3390/cells13010047 · Cited by 88

Protein prenylation: from discovery to prospects for cancer treatment

Gelb, M. H., Scholten, J. D., & Sebolt, J. S. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80034-3 · Cited by 77

Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2

Wissner, A., Fraser, H. L., Ingalls, C. L., Dushin, R. G., Floyd, M. B., Cheung, K., Nittoli, T., Ravi, M., Tan, X., & Loganzo, F. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.03.055 · Cited by 76

Signal transduction pathways and their relevance in human astrocytomas

Feldkamp, M. M., Lau, N. C., & Guha, A. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005800114912 · Cited by 75

Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials

Strawn, L. M., & Shawver, L. K. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.4.553 · Cited by 78

Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover

Prasad, N. K., Tandon, M., Badve, S., Snyder, P. W., & Nakshatri, H. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm213 · Cited by 75

Differential Utilization and Localization of ErbB Receptor Tyrosine Kinases in Skin Compared to Normal and Malignant Keratinocytes

Stoll, S. W., Kansra, S., Peshick, S. M., Fry, D. W., Leopold, W. R., Wiesen, J. F., Sibilia, M. C., Zhang, T., Werb, Z., Derynck, R., et al. (2001) · Neoplasia · doi:10.1038/sj.neo.7900170 · Cited by 76

Ectodomain Cleavage of ErbB-4

Cheng, Q.-C., Tikhomirov, O., Zhou, W., & Carpenter, G. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302111200 · Cited by 75

Protein tyrosine kinase inhibitors in cancer treatment

Traxler, P. M. (1997) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.7.6.571 · Cited by 74

Cholesterol Depletion Upregulates Involucrin Expression in Epidermal Keratinocytes Through Activation of p38

Jans, R., Atanasova, G., Jadot, M., & Poumay, Y. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23221.x · Cited by 73

Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance

Zha, G., Qin, H., Youssif, B. G. M., Amjad, M. W., Raja, M. A. G., Abdelazeem, A. H., & Bukhari, S. N. A. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.025 · Cited by 72

Differential function of STAT5 isoforms in head and neck cancer growth control

Leong, P. L., Xi, S., Drenning, S. D., Dyer, K. F., Wentzel, A. L., Lerner, E. C., Smithgall, T. E., & Grandis, J. R. (2002) · Oncogene · doi:10.1038/sj.onc.1205385 · Cited by 72

PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.

Bos, M., Mendelsohn, J. M., Kim, Y. M., Albanell, J., Fry, D. W., & Baselga, J. M. (1997) · PubMed · Cited by 199

Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice

Kunkel, M. W., Hook, K. E., Howard, C. T., Przybranowski, S. A., Roberts, B. J., Elliott, W. L., & Leopold, W. R. (1995) · Investigational New Drugs · doi:10.1007/bf00873135 · Cited by 59

Evaluation of Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Rae, J. M., & Lippman, M. E. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000010702.10130.29 · Cited by 29

Cytoskeletal and Morphological Changes Associated with the Specific Suppression of the Epidermal Growth Factor Receptor Tyrosine Kinase Activity in A431 Human Epidermoid Carcinoma

Nelson, J. M., & Fry, D. W. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3571 · Cited by 17

Biochemical and antiproliferative properties of 4-[Ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor

Fry, D. W., Nelson, J. M., Slintak, V., Keller, P. R., Rewcastle, G. W., Denny, W. A., Zhou, H., & Bridges, A. J. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00242-6 · Cited by 65